Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2069 in Obese Participants Without Diabetes
NCT07803991Phase 2Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYH2069 in obesity (9 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Relative percentage change in body weight from baseline at 28 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SYH2069
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07803991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803991.